

Mitsudomi, Tetsuya

Institution/Organization

Kindai University Faculty of Medicine

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

TM

Disclosure of Potential Conflicts

TM

COI Disclosure

Disclosures

AstraZeneca: advisory role, speaker fee Institutional, Personal

MSD: advisor role, speaker fee Institutional, Personal

Novartis: advisor role, speaker fee Personal

MSD: advisor role, speaker fee Institutional, Personal

Bristol Myers Squibb: advisor role, speaker fee Personal

Ono: advisor role, speaker fee Personal

Pfizer: advisor role, speaker fee Personal

Boehringer Ingelheim: advisor role, speaker fee Institutional , Personal

Eli-Lilly: Speaker fee Personal

Chugai: advisor role, speaker fee, Institutional , Personal

Janssen: advisor Personal

Amgen: advisor role Personal

Daiichi-Sankyo: advisory role Personal

COI Disclosure Certification

TM

Confidentiality Agreement

TM

Standards of Conduct Agreement

TM

IASLC's Tax-Exempt Status

TM

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Amounts listed for institutions includes clinical trials and research grants.

Amounts listed for personal are mostly honoraria for the invited speeches, advisory role, and/or manuscript preparation

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Outside organizations:

- emeritus member, Japan Lung Cancer Society
- emeritus member, Japanese Association of Chest Surgery
- emeritus member, Japanese Society of Medical Oncology
- council member, Japan Surgical Society

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Wakelee, Heather

Institution/Organization

Stanford University and Stanford Cancer Institute

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

HW

Disclosure of Potential Conflicts

HW

COI Disclosure

Disclosures

AstraZeneca: Advisory board, Institutional, Personal

Janssen Advisory: board Personal

Daiichi Sankyo: Advisory board Personal

Blueprint: Advisory board Personal

Mirati: Advisory role Personal

Helsinn: Advisory role Personal

Fishawack: Facilitate LTD Ongoing series of lectures Personal

Medscape AND Research to Practice AND Curio Science: Multiple CME events Personal

MJH holdings (PER): Multiple CME events/conferences Personal

UpToDate: Royalty payments, Personal

Axis Medical Education and Nexus Oncology: CME events, Personal

ACEA Biosciences: Local PI on trial Institutional

Arrys Therapeutics: Local PI of trial Institutional

BMS (and former Celgene): Local PI of trial and coordinating PI of IIT for former Celgene Institutional

Clovis Oncology: Local PI of trial Institutional

Genentech/Roche: Local PI of trial and Steering Committee Member Institutional

Merck: Local PI of trial and Steering Committee Member Institutional

Novartis: Local PI Institutional

Xcovery: Local PI of trial and Steering Committee Member Institutional

Seagen: Local PI of trial Institutional

COI Disclosure Certification

HW

Confidentiality Agreement

HW

Standards of Conduct Agreement

HW

IASLC's Tax-Exempt Status

HW

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Scagliotti, Giorgio

Institution/Organization

University of Torino

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

agree

Disclosure of Potential Conflicts

I have read it

COI Disclosure

Disclosures

AstraZeneca: Honoraria Personal

MSD: Honoraria Personal

Roche: Honoraria Personal

Takeda: Honoraria Personal

Pfizer: Honoraria Personal

Beigene: consulting role Personal

AstraZeneca: Consulting role Personal

COI Disclosure Certification

disclosed

Confidentiality Agreement

Agree

Standards of Conduct Agreement

Agree

IASLC's Tax-Exempt Status

agree

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Unrestricted grants to the institution for investigators' initiated studies:

MSD : A randomized phase II study of Pembrolizumab (MK- 3475) as maintenance therapy in patients with unresectable stage III non- small cell lung cancer treated with definitive chemo- radiotherapy

Tesaro (now GSK) : A Prospective Phase II Single- arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non- small- cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD- L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Fishawack Facilitate – personal fee > 10K

Are you conducting clinical trials with any oncology equipment companies?

Felip, Enriqueta

Institution/Organization

Hospital General Vall d'Hebron

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

EF

Disclosure of Potential Conflicts

EF

COI Disclosure

Disclosures

AMGEN: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

ASTRA ZENECA: ADVISORY BOARD, Personal

BAYER: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

BRISTOL-MYERS SQUIBB: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

ELI LILLY: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

F. HOFFMANN-LA ROCHE: ADVISORY BOARD/ SPEAKER'S BUREAU, Personal

GLAXO SMITH KLINE: ADVISORY BOARD, Personal

JANSSEN: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

MEDICAL TRENDS: ADVISORY BOARD, Personal

MEDSCAPE: SPEAKER'S BUREAU, Personal

MERCK SHARP & DOHME: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

MERCK SERONO: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

PEERVOICE: SPEAKER'S BUREAU, Personal

PFIZER: ADVISORY BOARD / SPEAKER'S BUREAU, Personal

SANOFI: ADVISORY BOARD, Personal

SYNEOS HEALTH: ADVISORY BOARD, Personal

SPRINGER: SPEAKER'S BUREAU, Personal

TAKEDA: ADVISORY BOARD, Personal

TOUCH MEDICAL: SPEAKER'S BUREAU, Personal

GRÍFOLS: INDEPENDENT MEMBER OF THE BOARD, Personal

COI Disclosure Certification

EF

Confidentiality Agreement

EF

Standards of Conduct Agreement

EF

IASLC's Tax-Exempt Status

EF

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Dr. Felip is Principal Investigator for the Clinical Trials but no income is received.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

* SEOM (Spanish Society of Medical Oncology): Leadership role. Dr. Felip is Vice- President of SEOM.

* ESMO (European Society of Medical Oncology): Member. Dr. Felip is member of the ESMO Nominating Committee and Compliance Committee.

* ETOP (European Thoracic Oncology Platform): Dr. Felip is member of the Scientific Committee of the European Thoracic Oncology Platform.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Ramalingam, Suresh

Board Member Information

Institution/Organization

Winship Cancer Institute of Emory University

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

SSR

Disclosure of Potential Conflicts

SSR

COI Disclosure

Disclosures

Amgen: Consultant, Institutional, Personal, The vast majority of the funds are directed to the institution to support research.

Bristol Myers Squibb: Consultant Institutional, Personal, the vast majority of the funds are directed to the institution to support research.

Astra Zeneca: Consultant Institutional, Personal

Advaxis: Research support, Institutional

Genmab: Consultant and research support Institutional, Personal

Merck: Consultant and research support Institutional, Personal

Glaxo Smithkline: Consultant and research support Institutional, Personal

Eisai: Consultant, Personal

Takeda: Research support, Institutional

American board of internal medicine: member of medical oncology exam committee, Personal

American Cancer Society: Section editor, Cancer journal, Personal

Research to practice: speaker at CME programs, Personal

Web MD: speaker at CME programs, Personal

Peerview: Speaker at CME programs, Personal

Onclive: Speaker at CME programs, Personal

Physicians Educational Resource: Speaker at CME program, Personal

Lilly Oncology: Consultant, Personal

COI Disclosure Certification

SSR

Confidentiality Agreement

SSR

Standards of Conduct Agreement

SSR

IASLC's Tax-Exempt Status

SSR

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

One issue that I would like to inform everyone is that I will assume the role of the Editor-in-Chief for the journal Cancer (American Cancer Society) on July 01, 2021 (this news release just came out today). I serve on the board of managers for PRECOG, LLC, which conducts clinical research in the United States. In addition, I serve on the board of Georgia CORE and Georgia Society of Clinical Oncology. I recently became the leader of the ASCO Cancer LinQ Leadership Council- this position actually wears the IASLC hat. I have been the chair of the ECOG- ACRIN

Thoracic Committee for the past 9 years. Best regards

Ram

Suresh S. Ramalingam, MD, FACP, FASCO

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Bezjak, Andrea

Institution/Organization

Princess Margaret Cancer Center

Primary Specialty

Radiation Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

AB

Disclosure of Potential Conflicts

AB

COI Disclosure

Disclosures

Princess Margaret Cancer Center: employment, Personal

University of Toronto: academic appointment, Personal

Astra Zeneca: Advisory Board, Personal

COI Disclosure Certification

AB

Confidentiality Agreement

AB

Standards of Conduct Agreement

AB

IASLC's Tax-Exempt Status

AB

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

I have no clinical trials with RT companies.

Brahmer, Julie

Institution/Organization

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

jrb

Disclosure of Potential Conflicts

jrb

COI Disclosure

Disclosures

Amgen: Advisory Board member, Personal

Merck: Advisory board member, Personal

BMS: Advisory board member, Personal

Eli Lilly: Advisory Board member, Personal

Genentech/Roche: Advisory board member, Personal

GlaxoSmithKline: Advisory board member/DSMB member, Personal

Sanofi: Advisory board member/ DSMB member, Personal

Regeneron: Advisory Board member, Personal

AstraZeneca: Advisory board member, Personal

Turning Point: Advisory Board member, Personal

Eisai: Advisory board member, Personal

AstraZeneca: grant funding, Institutional

BMS: Grant Funding, Institutional

Genentech: Grant funding, Institutional

RAPT Therapeutics, Inc: Clinical trial local PI, Institutional

Revolution Medicines: Clinical trial local PI, Institutional

PER: Cochair of yearly national meeting, Personal

BioAscend: Cochair of yearly national meeting, Personal

COI Disclosure Certification

JRB

Confidentiality Agreement

JRB

Standards of Conduct Agreement

JRB

IASLC's Tax-Exempt Status

JRB

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Fraser, Anne

Institution/Organization

Auckland District Health Board

Primary Specialty

Nursing

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

SAF

Disclosure of Potential Conflicts

SAF

COI Disclosure

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

SAF

Confidentiality Agreement

SAF

Standards of Conduct Agreement

SAF

IASLC's Tax-Exempt Status

SAF

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Herbst, Roy

Institution/Organization

Yale Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

RSH

Disclosure of Potential Conflicts

RSH

COI Disclosure

Disclosures

AstraZeneca: Pharmaceuticals Consulting, Personal

EMD Serono Inc.: Consulting, Personal

Immunocore: Consulting, Personal

Johnson and Johnson: Consulting, Personal

Merck & Company, Inc: Consulting, Personal

Mirati Therapeutics: Consulting, Personal

Novartis Oncology: Consulting, Personal

STCube Pharmaceuticals, Inc: Consulting, Personal

Xencor, Inc: Consulting, Personal

AstraZeneca: Pharmaceuticals Research (Clinical Trials), Institutional

Genentech/Roche: Research (Clinical Trials), Institutional

Merck & Company, Inc: Research (Clinical Trials), Institutional

Immunocore Holdings Limited: Board Member (non-executive/independent), Personal

to include stock options in 2021

Junshi Biosciences Co., Ltd.: Board Member (non-executive/independent), Personal

Cybrexa Therapeutics: Consulting, Personal

eEFFECTOR Therapeutics, Inc.: Consulting, Personal

Eli Lilly and Company: Consulting, Personal

I-Mab Biopharma: Consulting, Personal

Next Cure: Consulting, Personal

Bolt Biotherapeutics: Consultant, Personal, 2500 options (intrinsic value as of 4/21/2021: \$0.00)

COI Disclosure Certification

RSH

Confidentiality Agreement

RSH

Standards of Conduct Agreement

RSH

IASLC's Tax-Exempt Status

RSH

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Those institutional amounts are the research study support.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Mathias, Clarissa

Institution/Organization

Nucleo de Oncologia da Bahia

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

CM

Disclosure of Potential Conflicts

CM

COI Disclosure

Disclosures

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

CM

Confidentiality Agreement

CM

Standards of Conduct Agreement

CM

IASLC's Tax-Exempt Status

CM

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

I am currently the President of the Brazilian Society of Clinical Oncology and the Chair of the International Affairs Committee.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Noguchi, Masayuki

Institution/Organization

University of Tsukuba

Primary Specialty

Pathology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

yes

Disclosure of Potential Conflicts

yes

COI Disclosure

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

no potential Conflicts of Interest

Confidentiality Agreement

yes

Standards of Conduct Agreement

yes

IASLC's Tax-Exempt Status

yes

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Peled, Nir

Institution/Organization

Soroka Medical Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

NP

Disclosure of Potential Conflicts

NP

COI Disclosure

Disclosures

AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly , FoundationMedicine, Gaurdant 360, Merck, MSD, Novartis, NovellusDx, Pfizer, Roche, Takeda

Advisor & Honorarium from & Research Personal

COI Disclosure Certification

np

Confidentiality Agreement

NP

Standards of Conduct Agreement

NP

IASLC's Tax-Exempt Status

NP

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Clinical trials.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Thunnissen, Erik

Institution/Organization

VU University Medical Center

Primary Specialty

Pathology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

yes, et

Disclosure of Potential Conflicts

et

COI Disclosure

I have no potential Conflicts of Interest to disclose.

COI Disclosure Certification

et

Confidentiality Agreement

et

Standards of Conduct Agreement

difficult to read, et

IASLC's Tax-Exempt Status

et

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Van Schil, Paul

Institution/Organization

Antwerp University Hospital

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

PVS

Disclosure of Potential Conflicts

PVS

COI Disclosure

Disclosure List

Disclosures

AstraZeneca: External expert, Institutional

MSD: External expert, Institutional

National Cancer Institute (France): External expert, Institutional

BACTS (Belgian Association for Cardio-Thoracic Surgery): Treasurer - board member, Institutional

COI Disclosure Certification

PVS

Confidentiality Agreement

PVS

Standards of Conduct Agreement

PVS

IASLC's Tax-Exempt Status

PVS

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Yang, James Chih-Hsin

Institution/Organization

National Taiwan University Cancer Center

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

CHY

Disclosure of Potential Conflicts

CHY

COI Disclosure

Disclosures

Amgen: advisory board or consultancy, Institutional

AstraZeneca: advisory or consultancy services, Principle investigator of the sponsored trial, investigator initiated studies; Institutional, Personal

Bayer: advisory or consultancy services, Institutional

Boehringer Ingelheim: advisory or consultancy services, Institutional , Personal

Bristol Myers Squibb: advisory or consultancy services, Institutional

Daiichi Sankyo: advisory or consultancy services, Institutional

Eli Lilly: advisory or consultancy services, Institutional

Hansoh Pharmaceuticals: advisory or consultancy services, Personal

Merck KGaA: advisory or consultancy services Institutional, Personal

Merck Sharp and Dohme: advisory or consultancy services, principle investigator of sponsored study. Institutional, Personal

Novartis: advisory or consultancy services Institutional, Personal

Ono Pharmaceuticals: advisory or consultancy services, Institutional

Pfizer: advisory or consultancy services, Institutional

Roche Genentech: advisory or consultancy services, Institutional, Personal

Takeda Oncology: advisory or consultancy services, Institutional, Personal

Yuhan Pharmaceuticals: advisory or consultancy services, Personal

Esai: advisory or consultancy services, Institutional

Janssen: advisory or consultancy services, Institutional

Taiwan Lung Cancer Society: speech, moderator, chairperson of conferences, Personal

Taiwan Oncology Society: speech, moderator, chairperson of conferences, Personal

COI Disclosure Certification

CHY

Confidentiality Agreement

CHY

Standards of Conduct Agreement

CHY

IASLC's Tax-Exempt Status

CHY

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?

Zhou, Caicun

Institution/Organization

Tongji University Shanghai Pulmonary Hospital

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

ZCC

Disclosure of Potential Conflicts

ZCC

COI Disclosure

Disclosures

Lily China: honoraria as a speaker, Personal

Sanofi: honoraria as a speaker, Personal

BI: honoraria as a speaker, Personal

Roche China: honoraria as a speaker, Personal

MSD: honoraria as a speaker, Personal

Qilu: honoraria as a speaker, Personal

Hengrui: honoraria as a speaker and Advisor, Personal

Innovent Biologics: honoraria as a speaker and advisor, Personal

C-Stone: honoraria as a speaker, Personal

LUYE Pharma: honoraria as a speaker, Personal

TopAlliance Biosciences Inc: honoraria as a speaker and Advisor, Personal

Amoy Diagnostics: honoraria as a speaker, Personal

COI Disclosure Certification

ZCC

Confidentiality Agreement

ZCC

Standards of Conduct Agreement

ZCC

IASLC's Tax-Exempt Status

ZCC

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?